Assessing health-related quality of life in COPD: comparing generic and disease-specific instruments with focus on comorbidities by Margarethe E. Wacker et al.
RESEARCH ARTICLE Open Access
Assessing health-related quality of life
in COPD: comparing generic and
disease-specific instruments with
focus on comorbidities
Margarethe E. Wacker1*, Rudolf A. Jörres2, Annika Karch3, Sarah Wilke4, Joachim Heinrich5, Stefan Karrasch2,5,6,
Armin Koch3, Holger Schulz5, Henrik Watz7, Reiner Leidl1,8, Claus Vogelmeier9, Rolf Holle1 and for the
COSYCONET-Consortium
Abstract
Background: Chronic Obstructive Pulmonary Disease (COPD) influences different aspects of patient’s health-related
quality of life (HRQL). While disease-specific HRQL instruments focus on symptoms and functional impairments,
generic instruments cover a broader view on health. This study compares the generic EQ-5D-3 L and two
disease-specific questionnaires (St.-George’s Respiratory Questionnaire (SGRQ-C), COPD Assessment Test (CAT)) in
a comprehensive spectrum of COPD disease grades with particular attention on comorbidities and assesses the
discriminative abilities of these instruments.
Methods: Using data from the baseline visit of the German COPD cohort COSYCONET, mean HRQL scores in
different COPD grades were compared by linear regression models adjusting for age, sex, education, smoking
status, BMI, and low vs. high number of comorbidities or a list of several self-reported comorbid conditions.
Discriminative abilities of HRQL instruments to differentiate between COPD grades were assessed by standardized
mean differences.
Results: In 2,291 subjects in COPD GOLD grades 1–4 EQ-5D-3 L utility, EQ-5D VAS, SGRQ, and CAT were found
able to discriminate between COPD grades, with some limitations for the EQ-5D utility in mild disease. Both generic
and disease-specific HRQL instruments reflected the burden of comorbid conditions. The SGRQ showed the best
discrimination between COPD grades and was less influenced by comorbidities, while EQ-5D utility put a higher
weight on comorbid conditions. For all instruments, psychiatric disorders and peripheral artery disease showed the
strongest negative associations with HRQL.
Conclusion: All HRQL instruments considered reflect considerable impairment of HRQL in COPD patients,
worsening with increasing COPD grade and number of comorbidities. Findings may support clinical assessment,
choice of HRQL instrument in future studies, and parameterization of decision-analytic models.
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Background
Chronic Obstructive Pulmonary Disease (COPD) is a
common progressive disease that is characterized by
persistent airflow limitation and related to an enhanced
chronic inflammatory response in the airways and the
lung to noxious particles or gases [1]. Although prevent-
able and treatable, COPD represents an important public
health challenge which is projected to increase in coming
years because of continued exposure to risk factors such
as tobacco smoking, indoor and outdoor air pollution and
the aging population. The World Health Organization
predicted that COPD will become the fourth leading cause
of death worldwide by 2030 [2].
Patients with COPD usually experience a decrease in
their health-related quality of life (HRQL): COPD symp-
toms such as cough, dyspnea, and sputum production, as
well as acute exacerbations of the disease, and comorbidi-
ties which are ubiquitous in COPD patients contribute to
the overall severity of the disease [3–6].
HRQL as an important patient-reported outcome meas-
ure in COPD has gained attention in the last years both as
an individual descriptive measure as well as an endpoint
in clinical studies [7]. A large variety of generic and
disease-specific HRQL instruments with proven validity
and reliability is available to assess HRQL of COPD
patients [8]. While disease-specific instruments focus on
symptoms and functional impairments associated with
COPD, generic instruments are more widely applicable
irrespective of the underlying disease [7]. Therefore, they
can be used to compare HRQL of diseased and healthy
subjects or to compare the burden of different diseases.
Some generic questionnaires are used as utility instru-
ments e.g. for the calculation of quality-adjusted life years
(QALYs) in health economic evaluations. Nevertheless,
they may be less sensitive to special problems of a certain
disease than disease-specific instruments.
This paper describes generic as well as disease-specific
HRQL in a large cohort of patients with COPD comprising
all disease grades and compares assessment properties and
correlations of different HRQL instruments. HRQL instru-
ments are analyzed regarding their ability to differentiate
between COPD grades. Special attention is given to the im-
pact of comorbid conditions in COPD patients on generic
and disease-specific HRQL assuming that generic instru-
ments are more suitable to reflect the impact of comorbidi-
ties on health status than disease-specific instruments.
Furthermore, we analyze whether COPD and comorbidities
have additive effects on HRQL measures and whether this
is different for generic and disease-specific instruments.
Methods
Patients
This cross-sectional analysis is based on data from the
baseline visit of the German national COPD cohort
COSYCONET (German COPD and Systemic Conse-
quences - Comorbidities Network). In brief, COSYCONET
recruited 2,741 patients ≥ 40 years with physician-
diagnosed COPD by outpatient and inpatient healthcare
providers, patient groups, and media campaigns and ex-
amined them in 31 study centers all over Germany be-
tween September 2010 and December 2013. Exclusion
criteria were previous lung transplantation or lung volume
reduction surgery and lung malignancies. All participants
were clinically stable defined as no moderate or se-
vere exacerbations for at least 4 weeks at the time of
enrolment. Details on the cohort have been published
elsewhere [9, 10].
Lung function test and definition of COPD
Standardized spirometry was performed in the COSYC-
ONET cohort after bronchodilation with 400 μg salbuta-
mol and 80 μg ipratropium bromide. COPD was defined
as FEV1/FVC < 0.7 according to the GOLD criteria [1].
Patients were classified as grade 1 with FEV1 % pred. ≥
80, grade 2 with 50 ≤ FEV1 % pred. < 80, grade 3 with
30 ≤ FEV1 % pred. < 50 and grade 4 with FEV1 % pred. <
30, with predicted values based on reference equations
from the Global Lung Initiative (GLI) [11]. 430 partici-
pants from the cohort reporting a physician-diagnosed
COPD but with FEV1/FVC ≥ 0.7 were excluded from this
analysis as well as 20 participants with incomplete or
missing lung function data.
The BODE index [12] as established multidimensional
grading system in COPD was calculated in addition
based on body mass index (BMI, defined as weight in
kilograms/height in squared meters), FEV1 % pred., the
5-point modified Medical Research Council (mMRC)
dyspnea scale and the six-minute walking test which was
performed according to the criteria of the American
Thoracic Society [13]. The BODE index ranges from 0
to 10 points with higher values indicating worse health.
HRQL assessment
HRQL was assessed by self-administered questionnaires:
The St. George’s Respiratory Questionnaire in its COPD-
specific version (SGRQ-C) [14] and the COPD Assessment
Test (CAT) were used as disease-specific HRQL instru-
ments, and the EuroQol 5 dimensions (EQ-5D-3 L) as a
generic HRQL instrument.
The SGRQ-C with 40 items provides three component
scores for symptoms, activity and impact, and a total score.
Each score ranges from 0 (no impairment) to 100 (worst
possible). A difference of 4 unit points is considered the
minimum clinically important difference (MCID) [15].
The CAT is an 8-item, short and validated tool for the
assessment and monitoring of COPD [16]. Symptoms
are assessed on a scale from 0 to 5. The total score
ranges from 0 to 40 with higher scores representing
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worse health status. A MCID of 2 points has been pro-
posed [17].
The EQ-5D-3 L questionnaire is a preference-based
HRQL instrument with two parts. Part 1, the descriptive
section, covers five dimensions of health: mobility, self-
care, usual activities, pain/discomfort, and anxiety/de-
pression with three levels per item (no problems, some
problems, and extreme problems). An index-based
utility score (EQ-5D utility) ranging from 0 to 1 can be
calculated via a scoring algorithm which is based on val-
uations of representative general population samples.
We used the German time-trade-off tariff by Greiner
et al. for scoring [18]. A MCID for the utility score in
COPD patients has not yet been established. Based on
other diseases, it may range between 0.08-0.10 [19, 20].
Part 2, the valuation section, comprises a Visual Analog
Scale (VAS) for valuing health states on a rating scale
from 0 (worst imaginable health state) to 100 (best
imaginable health state). A MCID of 8 points has been
suggested in COPD patients with moderate to severe
disease [21].
All three HRQL instruments are designed to assess
current health status without specifying a recall period.
Comorbidities and covariables
Self-reported information on physician-diagnosed co-
morbid conditions was systematically obtained in semi-
structured interviews. We assessed 33 of these comorbid
conditions. The number of comorbid conditions was
summarized as a simple count. This approach has been
shown to be a good proxy for the burden of comorbidities
[22]. For defining groups with a low or a high number of
comorbidities, the median number of comorbidities (≤3
vs. >3) was used as cut-off. A list of all comorbidities con-
sidered can be found in the (Additional file 1: Figure S1).
Information on age, sex, school education (basic
(≤9 years), secondary (10–11 years), higher (≥12 years)),
and smoking status (current, former, and never smoker)
was collected by standardized questionnaires. BMI was
measured at the study centers and classified as normal
weight (18.5 ≤ BMI < 25), overweight (25 ≤BMI < 30), obese
(BMI ≥ 30), and underweight (BMI < 18.5).
Statistical analysis
Characteristics of COPD patients in different grades
were compared using analysis of variance (ANOVA) for
continuous variables and Chi2-tests for categorical
variables. For each HRQL instrument, the proportion
of participants with the worst or best possible health
state was determined to assess the presence of floor or
ceiling effects. Bivariate correlations between the HRQL
instruments and with clinical COPD measures were quan-
tified by Spearman’s rank coefficient.
To assess the association of COPD grades 1–4 with
HRQL and the discriminative ability of HRQL instru-
ments, linear regression models were performed adjust-
ing for age, sex, education, smoking status, BMI, and
low vs. high number of comorbidities. The number of
comorbid conditions as a continuous variable was con-
sidered in a sensitivity analysis instead of the dichoto-
mized variable. Adjusted mean HRQL scores resulting
from the regression models were reported for COPD
grade 1–4 as well as for the group with a low or high
number of comorbidities. Standardized mean differences
were calculated as the mean adjusted difference between
two COPD grades divided by their pooled (unadjusted)
standard deviation (SD) [23] in order to assess the mag-
nitude of the difference and to judge the ability of HRQL
instruments for discrimination. In additional models,
non-additive effects of COPD and comorbidity were
checked by interaction terms between COPD grades and
low or high number of comorbidities. Pseudo-R2 accord-
ing to Cox & Snell [24] were calculated to compare the
additional variance explained by COPD grade and/or
low vs. high number of comorbidities in models for all
HRQL instruments.
Further models were calculated controlling for all
single comorbidities instead of a comorbidity count to
identify the most important comorbid conditions for each
HRQL instrument, again adjusted for age, sex, education,
smoking status, and BMI.
Statistical analyses were performed using SAS software
(SAS Institute Inc., Cary, NC, USA, version 9.3), and p-
values of 0.05 or less were considered to be statistically
significant.
Results
The characteristics of the 2,291 COPD patients in grade 1
to 4 included for analysis are shown in Table 1. The major-
ity of patients was male with a mean age of 65 years, FEV1
of 52.5 % predicted, BODE index of 2.5, and 3.7 self-
reported comorbidities. Most of the COPD patients were in
GOLD grade 2 (42 %) and 3 (38 %). COPD grades were
comparable in their gender distribution while they differed
significantly regarding age, education, smoking status, BMI,
and the number of comorbidities.
Completeness of HRQL questionnaires, floor- and ceiling
effects and correlations
Completeness of questions was >98.8 % in all HRQL
instruments. COPD-specific HRQL instruments and EQ-
5D VAS showed no floor or ceiling effects. Regarding the
EQ-5D descriptive section, 18 % of patients reported the
best health state (11111).
With regard to the relationship between the HRQL in-
struments, correlations between EQ-5D utility index and
disease-specific HRQL scores were moderate (rho = -0.56
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for both CAT and SGRQ). Compared to the EQ-5D utility
score, the VAS showed a stronger correlation with the
CAT score (rho = -0.62) and the SGRQ total score
(rho = -0.65). Regarding the correlations of HRQL in-
struments with measures of disease severity, the highest
correlation was found between the SGRQ total or activity
score and the BODE index (rho = 0.61 or rho = 0.67).
COPD grade correlated best with the SGRQ total score
(rho = 0.40) and activity score (rho = 0.46). The BODE
index correlated better with HRQL instruments than
GOLD grade. For the number of comorbid conditions,
correlation was best for EQ-5D utility (rho = -0.29).
An overview of correlations can be found in Additional
file 1: Table S1.
HRQL scores in different COPD grades
In an unadjusted comparison, higher COPD grades showed
gradually worse generic and disease-specific HRQL scores
(Table 1). Individual variability within the COPD grades
was high (Additional file 1: Figure S2).
Table 2 shows the association of COPD grades with
HRQL measures after adjusting for possible confounders.
Patients in COPD grades 2–4 had significantly worse
HRQL across all instruments and scales compared to
COPD grade 1, except for the EQ-5D utility. For example,
COPD grade 2 was associated with a 5.7 point reduction
of the ED-5D VAS (p < 0.0001). This reduction increased
to 22.1 points for COPD grade 4 (p < 0.0001).
Adjusted mean HRQL scores by COPD grade are illus-
trated in Fig. 1. There were clear graduations between
COPD grades in all instruments except for the EQ-5D
utility in grade 1 and 2. Especially, the SGRQ score
seemed to increase linearly with disease grade. When
considering the number of comorbid conditions as a
continuous instead of a dichotomized variable, the ad-
justed means per COPD grade were virtually unchanged.
Table 1 Characteristics of the study population and unadjusted means of HRQL
Total sample COPD grade 1 COPD grade 2 COPD grade 3 COPD grade 4 p-value
n (%) 2,291 206 (9.0) 962 (42.0) 874 (38.1) 249 (10.9)
Age Mean age (SD) 65.1 (8.4) 66.2 (8.7) 65.7 (8.5) 65.0 (8.2) 62.1 (8.0) <0.0001
% < 55 years (n) 11.4 (262) 9.7 (20) 10.3 (99) 11.2 (98) 18.1 (45) <0.0001
% 55 – 64 years (n) 33.6 (769) 27.2 (56) 31.7 (305) 34.3 (300) 43.4 (108)
% 65 – 74 years (n) 43.2 (989) 48.1 (99) 44.5 (428) 43.8 (383) 31.7 (79)
% > 74 years (n) 11.8 (271) 15.1 (31) 13.5 (130) 10.6 (93) 6.8 (17)
Sex % male (n) 60.9 (1,396) 60.2 (124) 60.2 (579) 61.0 (533) 64.3 (160) 0.70
School education % basic education (n) 55.4 (1,270) 48.5 (100) 52.2 (502) 60.0 (524) 57.8 (144) 0.0002
% secondary education (n) 27.1 (620) 25.2 (52) 28.6 (275) 25.2 (220) 29.3 (73)
% higher education (n) 17.5 (401) 26.2 (54) 19.2 (185) 14.9 (130) 12.9 (32)
Smoking status % smokers (n) 24.7 (565) 30.1 (62) 28.8 (277) 21.7 (190) 14.5 (36) <0.0001
% former smokers (n) 68.8 (1,576) 62.6 (129) 63.6 (612) 72.7 (635) 80.3 (200)
% never smokers (n) 6.6 (150) 7.3 (15) 7.6 (73) 5.6 (49) 5.2 (13)
BMI Mean BMI (SD) a 26.7 (5.2) 26.6 (4.6) 27.4 (5.1) 26.4 (5.4) 24.4 (5.0) <0.0001
% normal weight (n) 37.1 (848) 36.4 (75) 32.6 (313) 38.5 (336) 49.8(124) <0.0001
% overweight (n) 37.1 (848) 42.2 (87) 38.9 (374) 36.2 (316) 28.5 (71)
% obese (n) 22.4 (512) 19.9 (41) 27.0 (259) 20.9 (182) 12.1 (30)
% underweight (n) 3.5 (81) 1.5 (3) 1.6 (15) 4.5 (39) 9.6 (24)
Mean FEV1 % pred. 52.5 (18.6) 88.6 (8.1) 62.7 (8.3) 40.7 (5.6) 24.8 (3.9) <0.0001
Mean BODE index (SD) b 2.5 (2.0) 0.4 (0.7) 1.3 (1.2) 3.6 (1.5) 5.3 (1.6) <0.0001
Comorbidities Mean number (SD) 3.7 (2.6) 4.1 (2.7) 3.9 (2.6) 3.7 (2.6) 3.1 (2.3) <0.0001
% low number of comorbidities (n) 52.6 (1,206) 48.5 (100) 50.6 (487) 52.9 (462) 63.1 (157) 0.003
% high number of comorbidities (n) 47.4 (1,085) 51.5 (106) 49.4 (475) 47.1 (412) 37.0 (92)
HRQL EQ-5D utility (SD) c 0.82 (0.20) 0.85 (0.18) 0.84 (0.19) 0.81 (0.21) 0.74 (0.24) <0.0001
EQ-5D VAS (SD) d 56.5 (19.6) 66.9 (17.4) 61.0 (18.8) 52.2 (18.8) 45.5 (17.8) <0.0001
CAT score (SD) e 18.2 (7.4) 14.2 (6.8) 16.9 (7.1) 19.4 (7.2) 22.1 (6.8) <0.0001
SGRQ score (SD) f 43.6 (20.0) 28.0 (15.8) 38.7 (19.1) 48.6 (17.9) 58.4 (18.0) <0.0001
an = 2,289, bn = 2,197, cn = 2,277, dn = 2,266, en = 2,276, fn = 2,272
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Figure 2 shows the calculated effect sizes to assess the
importance of the differences between COPD grades. The
SGRQ total score showed the best discrimination between
all grades of COPD. The CAT score and the VAS could
also equally differentiate between COPD grades both in
early and advanced disease grades, whereas the EQ-5D
utility differentiated much better between COPD patients
in grade 3 and 4 than in earlier grades.
HRQL instruments and comorbid conditions
Having 4 or more comorbidities was significantly associ-
ated with worse HRQL in all instruments, as shown in
Table 2. As to EQ-5D VAS and CAT, the effect estimate
of a high number of comorbidities compared to a low
number of comorbidities was approximately of the same
size than the difference between COPD grade 1 and 2.
For the SGRQ, the comorbidity estimate was lower than
the estimate of COPD grade 2, but still higher than the
suggested MCID. Compared to the estimates of the
COPD grades, the effect estimate of high comorbidity
was highest as to the EQ-5D utility, ranking between
grade 3 and 4. Adjusted mean HRQL scores by comorbid-
ity group are illustrated in Fig. 1. Combining with disease
severity, adjusted mean HRQL scores for comorbidity-
group by COPD grade are reported in the Additional
file 1: Table S2.
In additional models including interaction terms, the
effects of COPD grades and comorbidity on HRQL
measures were found to be additive, as all interaction
terms were non-significant (estimates shown in Additional
file 1: Table S3).
When controlling for COPD grades in addition to age,
sex, education, smoking status and BMI in regression
models, the increase of explained variance was higher
for the VAS, CAT, and SGRQ score than for the EQ-5D
utility. In contrast, controlling for a low vs. high number
of comorbidities resulted in a higher percentage of ex-
plained variance for the EQ-5D utility than for VAS,
CAT, and SGRQ. Details on the values of R2 are shown
in Table 3.
When considering single comorbidities instead of a
comorbidity count, psychological disorders comprising
depression and anxiety showed one of the highest effect
estimates in all models, both for generic and disease-
specific instruments (Table 4). Furthermore, peripheral
artery disease (PAD) ranked among the top 5 of comor-
bidities with negative effects on HRQL in all models as
well as sleep apnea except for the EQ-5D utility. Obesity
Table 2 Results of regression analyses
EQ-5D utility EQ-5D VAS CAT score SGRQ total score
Estimate p-value Estimate p-value Estimate p-value Estimate p-value
COPD Grade 4 -0.13 <0.0001 -22.11 <0.0001 7.92 <0.0001 31.71 <0.0001
Grade 3 -0.04 0.005 -14.61 <0.0001 4.98 <0.0001 20.41 <0.0001
Grade 2 -0.006 0.69 -5.67 <0.0001 2.47 <0.0001 10.28 <0.0001
Grade 1 ref. ref. ref. ref.
Comorbidities High number -0.09 <0.0001 -5.75 <0.0001 2.91 <0.0001 7.90 <0.0001
Low number ref. ref. ref. ref.
Age >74 years -0.01 0.59 -1.44 0.38 -2.05 0.001 1.20 0.45
65 – 74 years 0.01 0.36 1.04 0.43 -1.55 0.002 0.23 0.86
55 – 64 years -0.001 0.97 0.26 0.84 -0.60 0.23 0.26 0.84
<55 years ref. ref. ref. ref.
Sex Female -0.02 0.06 1.53 0.06 0.16 0.60 0.90 0.25
Male ref. ref. ref. ref.
School education Higher 0.05 <0.0001 3.08 0.003 -1.77 <0.0001 -4.58 <0.0001
Secondary 0.02 0.06 3.10 0.001 -0.88 0.01 -3.26 0.0002
Basic ref. ref. ref. ref.
Smoking status Current smoker -0.01 0.46 -0.13 0.94 0.74 0.25 1.19 0.47
Former smoker -0.02 0.29 0.29 0.85 0.18 0.77 1.45 0.34
Never smoker ref. ref. ref. ref.
BMI Overweight -0.03 0.007 -1.53 0.09 0.14 0.68 1.50 0.08
Obese -0.06 <0.0001 -4.68 <0.0001 1.64 <0.0001 6.40 <0.0001
Underweight 0.002 0.93 -5.59 0.01 0.87 0.28 1.97 0.34
Normal weight ref. ref. ref. ref.
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was also significantly associated with a considerably re-
duced HRQL in all instruments.
For the disease-specific instruments as well as the
VAS, the effect estimates of all single comorbid condi-
tions were comparable to or smaller than the estimate of
COPD grade 2 (Table 4). For the EQ-5D utility, all esti-
mates of the 5 comorbidities with the largest effects
ranged between the effect of COPD grade 3 (-0.05) and
grade 4 (-0.14).
Discussion
This study performed a comparison of the most frequently
used generic and disease-specific HRQL instruments in a
large cohort of COPD patients in all levels of airflow limi-
tation with particular attention on the association with a
comprehensive list of comorbid conditions.
Our study confirms that mean scores of SGRQ, CAT,
EQ-5D utility, and EQ-5D VAS worsen with increasing
COPD grade, despite high variability within each grade.
EQ-5D utility and VAS as generic HRQL instruments
and SGRQ and CAT as disease-specific instruments were
found able to discriminate between COPD grades, with
some limitations for the EQ-5D utility in mild COPD.
Utility results which are based on population preferences
and therefore introduce external HRQL valuation put
the highest weight on comorbid conditions. However,
disease-specific HRQL instruments also reflected the
burden of comorbid conditions. Non-additive effects of
COPD and comorbidity were not observed. When focus-
ing on single comorbid conditions, psychiatric disorders
and peripheral artery disease ranked among the top 5
comorbid conditions with negative associations with
HRQL for all instruments. Sleep apnoea, brain deficiency,
asthma, and heart disease were also important contribu-
tors to low HRQL.
Regarding mean HRQL scores per COPD grade or
correlation of disease-specific and generic HRQL mea-
sures, our results are in line with previous studies. Despite
the differences in underlying populations, the mean CAT
scores of our study fit very well in the range of means
reported in a systematic review on studies using the CAT
by Gupta et al. [25]. In a small sample of US veterans in
COPD grades 1–4 (n = 120), Pickard et al. reported corre-
lations between EQ-5D utility or VAS and SGRQ total
score similar to our findings [26]. The EQ-5D VAS means,
which were considerably higher than in our study, differed
Fig. 1 Adjusted mean EQ-5D utilities, EQ-5D VAS, CAT score, SGRQ score by COPD grade 1-4 and comorbidity group
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Fig. 2 Standardized absolute mean differences between COPD grades
Table 3 Comparison of pseudo-R-squareda of different models (percentage of variance explained by different models)
Models considering… EQ-5D utility EQ-5D VAS CAT score SGRQ total score
Age, sex, education, smoking status, BMI category 0.034 0.029 0.041 0.043
Age, sex, education, smoking status, BMI category and COPD grade 0.063 0.125 0.112 0.201
Age, sex, education, smoking status, BMI category and low/high
number of comorbidities
0.074 0.048 0.074 0.075
Age, sex, education, smoking status, BMI category, COPD grade
and low/high number of comorbidities
0.106 0.145 0.149 0.238
a R2 according to Cox & Snell [24]
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between COPD grades 1–4, while EQ-5D utilities did not.
In line with our results, best discriminative properties be-
tween COPD grades were reported for the SGRQ in this
study.
Our results showed clear HRQL differences between
COPD grade 1 and 2 (except for EQ-5D utility), while
some previous studies did not observe HRQL differences
between milder COPD grades. E.g., Jones et al. did not
find differences in SGRQ total score and the generic SF-
12 questionnaire between primary care COPD patients in
grade 1 and 2. This might be due to the fact that reported
SGRQ means for grade 1 were more than 10 points higher
than in our sample, while mean values for grades 2, 3 and
4 as reported in Jones et al. were comparable to our re-
sults [27]. In the same population, Jones et al. did not find
significant differences in CAT scores between COPD
grade 1 and 2 [28]. A possible explanation for this lack of
differences between these grade 1 and 2 patients may be
that symptoms and HRQL impairment are important
drivers for the patients to see their primary care physician.
For health-economic evaluations in COPD, it is
important to know the discriminative abilities of the
EQ-5D questionnaire because it is frequently applied for
determining utilities needed for the calculations of
quality-adjusted life years (QALYs) [29]. Based on data
from UPLIFT, a large COPD trial covering 13 countries,
Rutten-van Mölken et al. investigated discriminative
abilities of the EQ-5D questionnaire in COPD patients
[29]. This study found better discriminative properties of
the EQ-5D utility in higher COPD grades, but did not
include COPD grade 1. When comparing EQ-5D util-
ities, it has to be kept in mind that utilities depend on
the underlying country-specific tariff and methods (time
trade off vs. standard gamble) used for their calculation.
Furthermore, ceiling effects may limit the sensitivity of
the utility.
There seems to be a consensus that COPD patients
with a higher number of comorbid conditions have a
worse HRQL [27, 28, 30–34]. Several previous studies
supplied evidence that comorbidities in patients with
COPD are associated with worse COPD-specific HRQL
scores [6, 27, 28, 31, 35, 36]. In a hospital-based COPD
cohort, Koskela et al. also found that a generic HRQL
instrument better captured the effects of comorbid con-
ditions but that these conditions were also associated
with COPD-specific HRQL [3]. For COPD patients with
three or more comorbid conditions, Jones et al. reported
significantly worse CAT (+2.5 units) [28] and SGRQ
scores (approx. +8 units) [27] than for patients without
or with 1–2 comorbidities. Despite referring to different
comorbid conditions, these extra units correspond well
to the estimates of high comorbidity found in our study.
When focusing on single comorbid conditions, especially
mental health problems are often reported contributors to
decreased HRQL in COPD [3, 5, 6, 31, 34, 37]. This was
confirmed by our analysis. In general, a direct comparison
of the effects of single comorbidities on HRQL in COPD
patients is often hampered by different conditions consid-
ered and diverging definitions. Depression, anxiety, and
PAD which we identified as the most important comorbid-
ities in our study, were also included in the recently pub-
lished COMCOLD index that identified five comorbidities
with the highest effect on the VAS [38]. Further compari-
son with the two additional comorbidities of this index
(symptomatic heart disease and cerebrovascular disease)
was not possible due to differences in definitions.
Urff et al. reported that COPD patients with depression
or heart failure had considerably lower disease-specific
HRQL as measured by the Clinical COPD Questionnaire
(CCQ) [36] and explained this finding by overlapping
symptoms of COPD and depression or heart failure. Hav-
ing the items of EQ-5D, CAT, and SGRQ in mind, another
reason could be that there is an overlap of these instru-
ments with regard to psychological and mobility aspects
of health. Therefore, it is not surprising that especially
psychological disorders and PAD showed the strongest
associations with the HRQL scores in our analysis. We did
not consider dyspnea and exacerbation frequency in our
multivariate analysis. As the CAT and SGRQ include dys-
pnea and symptoms of exacerbations already in their
Table 4 Effect estimates of top 5 single comorbid conditions with significant negative association with HRQL scores
Rank EQ-5D utility EQ-5D VAS CAT SGRQ
1 Psychiatric
disorder a
-0.09 (p < 0.0001) Brain
deficiency b
-5.9 (p = 0.001) Psychiatric
disorder a
2.5 (p < 0.0001) Psychiatric
disorder a
7.2 (p < 0.0001)
2 Arthritis -0.06 (p < 0.0001) Psychiatric
disorder a
-5.3 (p < 0.0001) Asthma 1.7 (p < 0.0001) PAD 5.0 (p < 0.0001)
3 PAD -0.05 (p < 0.0001) PAD -3.4 (p = 0.005) Sleep apnea 1.5 (p = 0.002) Brain deficiency 4.6 (p = 0.005)
4 Arthrosis -0.05 (p = 0.0003) Asthma -3.4 (p = 0.001) Heart disease c 1.5 (p < 0.0001) Sleep apnea 4.3 (p = 0.0004)
5 Migraine -0.05 (p < 0.0001) Sleep apnea -2.8 (p = 0.03) PAD 1.4 (p = 0.002) Heart disease c 4.1 (p < 0.0001)
all models adjusted for age, sex, school education, smoking status, BMI category, and GOLD grade
acomprising anxiety, depression, psychoses
bcomprising weakness of memory, disorientation, confusion
ccomprising cardiac arrhythmia, cardiac insufficiency, narrow coronary vessel, angina pectoris
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items, controlling for these factors as explanatory variables
would cause problems of circularity. The finding that the
multidimensional BODE index showed higher correlation
with HRQL scores than COPD grades is in line with this
reasoning because BODE includes mMRC as a measure of
dyspnea and the 6-minute-walking-test as a measure of
physical capacity.
Further explanations for the ability of disease-specific
HRQL instruments to reflect the burden of comorbidity
need to be addressed in future research.
Several strengths of our study have to be considered.
Based on a large patient sample comprising all COPD
grades, our analysis had sufficient power to detect differ-
ences between grades. A comprehensive list of comorbid
conditions was available and possible interactions be-
tween COPD and comorbidity were analyzed. Therefore,
the results of our observational study might be more
generalizable than results from clinical trials where pa-
tients with comorbidities are often excluded.
There are, however, also potential limitations: First,
since only cross-sectional data were available, we were
not able to investigate the responsiveness of HRQL instru-
ments or sensitivity to change over time. Second, data
on physician-diagnosed comorbidities were self-reported
which might limit their validity, and no information on
the severity of comorbid conditions was available. Further-
more, comorbid conditions were summarized and dichot-
omized without weighting. However, this approach has
been shown to perform just as well as weighted scores to
quantify the impact of comorbidities on disease-specific
HRQL in COPD patients [22].
Nevertheless, from a research perspective, our direct
comparison of HRQL instruments did not show a clear
ranking. The decision for a generic or disease-specific
instrument must be based on the purpose of HRQL meas-
urement. Cross-sectional comparisons of COPD patients
(with or without control subjects) or a longitudinal moni-
toring of disease progression pose different demands on
HRQL instruments. Researchers are responsible to ensure
that the chosen HRQL instrument addresses the problems
of the research questions. While generic instruments allow
comparisons of groups with different conditions, may
support the identification of unexpected HRQL issues,
and are need for the calculation of QALYs in economic
evaluations, disease-specific instruments are more likely
to detect small, but relevant changes [39]. Furthermore,
by focusing on relevant dimensions of the disease, disease-
specific instruments may have a higher acceptability
among patients and thus increased responsiveness.
However, we have shown that the effect of comorbid
conditions on HRQL was both apparent in generic and to
a smaller degree in COPD-specific HRQL measures. This
finding is consistent with studies from other diseases [40].
To cover all aspects of HRQL in COPD, both generic and
disease-specific instruments should be used in the ideal
case. With regard to economic evaluations, further re-
search is needed towards the discriminative properties of
the new EQ-5D 5-level version in COPD.
From a clinical perspective, our results underline the
need for a holistic approach for COPD healthcare with a
mandatory screening for comorbidities, assessment of
HRQL and in consequence a multidisciplinary treatment
as generic and also COPD-specific health status could
be improved [41].
Conclusion
This large observational study confirms that HRQL is
considerably impaired in COPD patients and worsens
with disease deterioration and higher comorbidity. Find-
ings underline the need of diagnosing and treating comor-
bid conditions in COPD patients as generic and also
COPD-specific health status could be improved. Results
may further be useful for choosing HRQL instruments in
future clinical studies, and for parameterizing decision-
analytic COPD models.
Ethics approval and consent to participate
The COSYCONET study complies with the Declaration
of Helsinki and Good Clinical Practice Guidelines and
has been approved by the ethics committee of the med-
ical faculty of the Philipps-Universität Marburg, the local
ethics committees of the participating centers (a list of
all participating study centers can be found here: http://
www.asconet.net/html/cosyconet/studzent) and by the
concerned data security authority (data security agency
of the federal states of Hesse, Baden-Württemberg,
Lower-Saxony, and Saarland). All participants provided
written informed consent.
Availability of data and materials
The full dataset supporting the conclusions of this
article is available upon request and application from the





Additional file 1: Table S1. Correlations between HRQL instruments
and with GOLD grade and BODE as clinical measures: Spearman Correlation
Coefficients. Table S2. Adjusted mean EQ-5D utilities, EQ-5D VAS, CAT score,
SGRQ total scores for COPD grade 1–4 stratified for group with low (≤3) or
high (>3) number of comorbidities. Table S3. Results of regression models
considering interactions between COPD grades and low/high number of
comorbidity. Figure S1. Lifetime prevalence of self-reported comorbidities (%)
in the study population. Figure S2. HRQL scores by FEV1 % pred.: non-
parametric quantile regression: quantile fit plots for FEV1 % pred. (DOC 258 kb)
Wacker et al. BMC Pulmonary Medicine  (2016) 16:70 Page 9 of 11
Abbreviations
ANOVA: analysis of variance; BMI: body mass index; BODE: body-mass index,
airflow obstruction, dyspnea and exercise capacity index; CAT: COPD
assessment test; COPD: chronic obstructive pulmonary disease;
COSYCONET: German COPD and Systemic Consequences - Comorbidities
Network; EQ-5D-3 L: EuroQol 5 dimensions questionnaire with 3 levels;
FEV1: forced expiratory volume in 1 second; FVC: forced vital capacity;
HRQL: health-related quality of life; MCID: minimum clinically important
difference; PAD: peripheral artery disease; QALY: quality-adjusted life year;
SD: standard deviation; SGRQ-C: St. George’s Respiratory Questionnaire,
COPD-specific version; VAS: visual analog scale.
Competing interests
CV reports personal fees from Almirall, AstraZeneca, Boehringer Ingelheim,
Chiesi, GlaxoSmithKline, Grifols, Janssen, Mundipharma, Novartis, Takeda, and
Cipla outside the submitted work. All other authors have no relevant
conflicts of interest.
Authors’ contributions
MW and RH conceptualized the paper. MW, AKa, RH performed the statistical
analysis and interpreted the data. MW, RH drafted the manuscript. RJ, HS, SK,
JH, AKo, HW, RL, CV were involved in the coordination of the study and all
commented on drafts of the paper. All authors critically reviewed each draft






This work was supported by the Competence Network Asthma and COPD
(ASCONET). The COSYCONET COPD Cohort is funded by the German Federal
Ministry of Education and Research (BMBF) with grant numbers 01GI0881,
01GI0882 and by unrestricted grants from several pharmaceutical companies.
Author details
1Institute of Health Economics and Health Care Management, Helmholtz
Zentrum München GmbH - German Research Center for Environmental
Health, Comprehensive Pneumology Center Munich (CPC-M), Member of the
German Center for Lung Research (DZL), Ingolstädter Landstr. 1, 85764
Neuherberg, Germany. 2Institute and Outpatient Clinic for Occupational,
Social and Environmental Medicine, Ludwig-Maximilians-Universität
München, Ziemssenstr. 1, 80336 Munich, Germany. 3Institute for Biostatistics,
Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany.
4Department of Research & Education, CIRO, Hornerheide 1, 6085, NM, Horn,
The Netherlands. 5Institute of Epidemiology I, Helmholtz Zentrum München
GmbH - German Research Center for Environmental Health, Comprehensive
Pneumology Center Munich (CPC-M), Member of the German Center for
Lung Research (DZL), Ingolstädter Landstr. 1, 85764 Neuherberg, Germany.
6Institute of General Practice, University Hospital Klinikum rechts der Isar,
Technische Universität München, Orleansstr. 47, 81667 Munich, Germany.
7Pulmonary Research Institute at LungenClinic Grosshansdorf, Airway
Research Center North (ARCN), Member of the German Center for Lung
Research (DZL), Wöhrendamm 80, 22927 Grosshansdorf, Germany. 8Institute
of Health Economics and Health Care Management, Munich Center of Health
Sciences, Ludwig-Maximilians-Universität München, Ludwigstr. 28/RG, 80539
Munich, Germany. 9Department of Respiratory Medicine, University of
Marburg, University Giessen and Marburg Lung Center (UGMLC), Member of
the German Center for Lung Research (DZL), Baldingerstraße, 35043 Marburg,
Germany.
Received: 25 February 2016 Accepted: 1 May 2016
References
1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global
Strategy for the Diagnosis, Management, and Prevention of Chronic
Obstructive Pulmonary Disease (Update 2015). Available from: http://www.
goldcopd.org/ Accessed 20 Jan 2016.
2. Mathers CD, Loncar D. Projections of global mortality and burden of disease
from 2002 to 2030. PLoS Med. 2006;3(11):e442.
3. Koskela J, Kilpelainen M, Kupiainen H, Mazur W, Sintonen H, Boezen M,
Lindqvist A, Postma D, Laitinen T. Co-morbidities are the key nominators of
the health related quality of life in mild and moderate COPD. BMC Pulm
Med. 2014;14:102.
4. Srivastava K, Thakur D, Sharma S, Punekar YS. Systematic review of
humanistic and economic burden of symptomatic chronic obstructive
pulmonary disease. PharmacoEconomics. 2015;33(5):467–88.
5. Huber MB, Wacker ME, Vogelmeier CF, Leidl R. Comorbid Influences on
generic health-related quality of life in COPD: a systematic review. PLoS
One. 2015;10(7):e0132670.
6. Burgel P-R, Escamilla R, Perez T, Carré P, Caillaud D, Chanez P, Pinet C,
Jebrak G, Brinchault G, Court-Fortune I, et al. Impact of comorbidities on
COPD-specific health-related quality of life. Respir Med. 2013;107(2):233–41.
7. Jones PW. Health status measurement. In: Kolb M, Vogelmeier CF, editors.
Outcomes in Clinical Trials. Lausanne: European Respiratory Society; 2013. p.
96-104.
8. Weldam SWM, Schuurmans MJ, Liu R, Lammers J-WJ. Evaluation of quality
of life instruments for use in COPD care and research: a systematic review.
Int J Nurs Stud. 2013;50(5):688–707.
9. Karch A, Vogelmeier C, Welte T, Bals R, Kauczor HU, Biederer J, Heinrich J,
Schulz H, Gläser S, Holle R, et al. The German COPD cohort COSYCONET:
aims, methods and descriptive analysis of the study population at baseline.
Respir Med. 2016;111:39–46.
10. Jorres RA, Welte T, Bals R, Koch A, Schnoor M, Vogelmeier C. Systemic
manifestations and comorbidities in patients with chronic obstructive
pulmonary disease (COPD) and their effect on clinical state and course of
the disease–an overview of the cohort study COSYCONET. Dtsch Med
Wochenschr. 2010;135(10):446–9.
11. Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, Enright PL,
Hankinson JL, Ip MSM, Zheng J, et al. Multi-ethnic reference values for
spirometry for the 3–95-yr age range: the global lung function 2012
equations. Eur Respir J. 2012;40(6):1324–43.
12. Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA,
Pinto Plata V, Cabral HJ. The Body-Mass Index, Airflow Obstruction, Dyspnea,
and Exercise Capacity Index in Chronic Obstructive Pulmonary Disease.
N Engl J Med. 2004;350(10):1005–12.
13. American Thoracic Society. ATS statement: guidelines for the six-minute
walk test. Am J Respir Crit Care Med. 2002;166(1):111-7.
14. Meguro M, Barley EA, Spencer S, Jones PW. Development and validation of
an improved, COPD-specific version of the St. George Respiratory
Questionnaire. Chest. 2007;132(2):456–63.
15. Jones PW. Interpreting thresholds for a clinically significant change in health
status in asthma and COPD. Eur Respir J. 2002;19(3):398–404.
16. Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N.
Development and first validation of the COPD Assessment Test. Eur Respir J.
2009;34(3):648–54.
17. Kon SSC, Canavan JL, Jones SE, Nolan CM, Clark AL, Dickson MJ, Haselden
BM, Polkey MI, Man WDC. Minimum clinically important difference for
the COPD Assessment Test: a prospective analysis. Lancet Respir Med.
2014;2(3):195–203.
18. Greiner W, Claes C, Busschbach JJ, von der Schulenburg JM. Validating the
EQ-5D with time trade off for the German population. Eur J Health Econ.
2005;6(2):124–30.
19. Kim SK, Kim SH, Jo MW, Lee SI. Estimation of minimally important
differences in the EQ-5D and SF-6D indices and their utility in stroke.
Health Qual Life Outcomes. 2015;13:32.
20. Pickard AS, Neary MP, Cella D. Estimation of minimally important differences in
EQ-5D utility and VAS scores in cancer. Health Qual Life Outcomes. 2007;5:70.
21. Zanini A, Aiello M, Adamo D, Casale S, Cherubino F, Della Patrona S,
Raimondi E, Zampogna E, Chetta A, Spanevello A. Estimation of minimal
clinically important difference in EQ-5D visual analog scale score after
pulmonary rehabilitation in subjects with COPD. Respir Care. 2015;60(1):88–95.
22. Putcha N, Puhan MA, Drummond MB, Han MK, Regan EA, Hanania NA,
Martinez CH, Foreman M, Bhatt SP, Make B, et al. A simplified score to
quantify comorbidity in COPD. PLoS ONE. 2014;9(12):e114438.
23. Grissom RJ, Kim JJ. Effect Sizes for Research: Univariate and Multivariate
Applications. New York: Taylor & Francis Group; 2012.
24. Cox DR SE: Analysis of Binary Data. Monographs on Statistics and Applied
Probability 32; Chapmann & Hall/CRC; 1989.
Wacker et al. BMC Pulmonary Medicine  (2016) 16:70 Page 10 of 11
25. Gupta N, Pinto LM, Morogan A, Bourbeau J. The COPD assessment test: a
systematic review. Eur Respir J. 2014;44(4):873–84.
26. Pickard AS, Yang Y, Lee TA. Comparison of health-related quality of life
measures in chronic obstructive pulmonary disease. Health Qual Life
Outcomes. 2011;9:26.
27. Jones PW, Brusselle G, Dal Negro RW, Ferrer M, Kardos P, Levy ML, Perez T,
Soler-Cataluna JJ, van der Molen T, Adamek L, et al. Health-related quality of
life in patients by COPD severity within primary care in Europe. Respir Med.
2011;105(1):57–66.
28. Jones PW, Brusselle G, Dal Negro RW, Ferrer M, Kardos P, Levy ML, Perez T,
Soler Cataluna JJ, van der Molen T, Adamek L, et al. Properties of the
COPD assessment test in a cross-sectional European study. Eur Respir J.
2011;38(1):29–35.
29. Rutten-van Molken MP, Oostenbrink JB, Tashkin DP, Burkhart D, Monz BU.
Does quality of life of COPD patients as measured by the generic EuroQol
five-dimension questionnaire differentiate between COPD severity stages?
Chest. 2006;130(4):1117–28.
30. van Manen JG, Bindels PJ, Dekker EW, Ijzermans CJ, Bottema BJ, van der Zee
JS, Schade E. Added value of co-morbidity in predicting health-related
quality of life in COPD patients. Respir Med. 2001;95(6):496–504.
31. Sundh J, Johansson G, Larsson K, Linden A, Lofdahl CG, Janson C,
Sandstrom T. Comorbidity and health-related quality of life in patients with
severe chronic obstructive pulmonary disease attending Swedish secondary
care units. Int J Chron Obstruct Pulmon Dis. 2015;10:173–83.
32. Smith MC, Wrobel JP. Epidemiology and clinical impact of major
comorbidities in patients with COPD. Int J Chron Obstruct Pulmon Dis.
2014;9:871–88.
33. Hong JY, Kim SY, Chung KS, Kim EY, Jung JY, Park MS, Kang YA, Kim SK,
Chang J, Kim YS. Factors associated with the quality of life of Korean COPD
patients as measured by the EQ-5D. Qual Life Res. 2015;24(10):2549–58.
34. Vanfleteren LE, Spruit MA, Groenen M, Gaffron S, van Empel VP, Bruijnzeel
PL, Rutten EP, Op ’t Roodt J, Wouters EF, Franssen FM. Clusters of
comorbidities based on validated objective measurements and systemic
inflammation in patients with chronic obstructive pulmonary disease.
Am J Respir Crit Care Med. 2013;187(7):728–35.
35. Sundh J, Stallberg B, Lisspers K, Montgomery SM, Janson C. Co-morbidity,
body mass index and quality of life in COPD using the Clinical COPD
Questionnaire. COPD. 2011;8(3):173–81.
36. Urff M, van den Berg JW, Uil SM, Chavannes NH, Damoiseaux RA.
Depression and heart failure associated with clinical COPD questionnaire
outcome in primary care COPD patients: a cross-sectional study. NPJ Prim
Care Respir Med. 2014;24:14066.
37. Tsiligianni I, Kocks J, Tzanakis N, Siafakas N, van der Molen T. Factors that
influence disease-specific quality of life or health status in patients with
COPD: a review and meta-analysis of Pearson correlations. Prim Care Respir
J. 2011;20(3):257–68.
38. Frei A, Muggensturm P, Putcha N, Siebeling L, Zoller M, Boyd CM, ter Riet G,
Puhan MA.. Five comorbidities reflected the health status in patients with
chronic obstructive pulmonary disease: the newly developed COMCOLD
index. J Clin Epidemiol. 2014;67(8):904–11.
39. Fletcher A, Gore S, Jones D, Fitzpatrick R, Spiegelhalter D, Cox D. Quality of
life measures in health care. II: Design, analysis, and interpretation. BMJ.
1992;305(6862):1145–8.
40. Xuan J, Kirchdoerfer LJ, Boyer JG, Norwood GJ. Effects of comorbidity on
health-related quality-of-life scores: an analysis of clinical trial data. Clin Ther.
1999;21(2):383–403.
41. Hillas G, Perlikos F, Tsiligianni I, Tzanakis N. Managing comorbidities in
COPD. Int J Chron Obstruct Pulmon Dis. 2015;10:95–109.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Wacker et al. BMC Pulmonary Medicine  (2016) 16:70 Page 11 of 11
